# Supplemental table 3. Cox regression univariate and multivariate analysis including all covariates potentially impacting on overall survival

|  |  |  |
| --- | --- | --- |
| **Variable** | **Univariate analysis** | **Multivariate analysis** |
| **HR** | **95% CI** | **p** | **HR** | **95% CI** | **p** |
| *EGFR* T790M positive status | 0.569 | 0.361 | 0.898 | **0.015** | 0.523 | 0.303 | 0.903 | **0.020** |
| *EGFR* exon 19 deletion vs other mutations | 0.625 | 0.404 | 0.968 | **0.035** | 0.680 | 0.416 | 1.113 | 0.125 |
| Adenocarcinoma histology | 0.754 | 0.275 | 2.067 | 0.583 |  |  |  |  |
| Smoking | 0.899 | 0.559 | 1.446 | 0.662 |  |  |  |  |
| Stage at diagnosis (IV vs IIIB/IIIC) | 0.943 | 0.433 | 2.057 | 0.883 |  |  |  |  |
| Male sex | 0.946 | 0.603 | 1.483 | 0.808 |  |  |  |  |
| Median age at diagnosis (≥65 years vs <65 years) | 1.149 | 0.733 | 1.802 | 0.545 |  |  |  |  |
| ECOG PS at diagnosis (2 vs 0-1) | 1.209 | 0.485 | 3.012 | 0.684 |  |  |  |  |
| Previous treatment with afatinib | 1.228 | 0.773 | 1.951 | 0.384 |  |  |  |  |
| Charlson (>6 vs 6) | 1.342 | 0.808 | 2.229 | 0.256 |  |  |  |  |
| Baseline liver metastases | 1.376 | 0.864 | 2.190 | 0.179 |  |  |  |  |
| Bone metastases at diagnosis | 1.389 | 0.891 | 2.169 | 0.147 |  |  |  |  |
| Previous TKI best response (SD/PD vs CR/PR) | 1.523 | 0.975 | 2.378 | 0.065 |  |  |  |  |
| Liver metastases at diagnosis | 1.554 | 0.898 | 2.689 | 0.115 |  |  |  |  |
| Brain metastases at diagnosis | 1.555 | 0.908 | 2.662 | 0.107 |  |  |  |  |
| Baseline bone metastases | 1.748 | 1.097 | 2.786 | **0.019** | 1.901 | 1.135 | 3.181 | **0.015** |
| Baseline brain metastases | 1.780 | 1.087 | 2.916 | **0.022** | 1.764 | 1.051 | 2.959 | **0.032** |
| Best response to treatment (SD/PD vs CR/PR) | 2.753 | 1.773 | 4.274 | **0.001** | 2.213 | 1.360 | 3.602 | **0.001** |

Significant values are highlighted in bold. HR, hazard ratio, 95%CI, 95% confidence interval, TKI, tyrosine kinase inhibitor, SD, stable disease, PD, progressive disease, CR, complete response, PR, partial response, ECOG PS, Eastern Cooperative Oncology Group Performance Status